[1]
|
Oriel, K.A., Hartenbach, E.M. and Remington, P.L. (1999) Trends in United States ovarian cancer mortality, 1979-1995. Obstetrics & Gynecology, 93, 30-33.
http://dx.doi.org/10.1016/S0029-7844 (98)00397-4
|
[2]
|
Duncan, T.J., Al-Attar, A., Rolland, P., Scott, I.V., Deen, S., Liu, D.T., Spendlove, I. and Durrant, L.G. (2008) Vascular endothelial growth factor expression in ovarian cancer: A model for targeted use of novel therapies? Clinical Cancer Research, 14, 3030-3035.
http://dx.doi.org/10.1158/1078-0432. CCR-07-1888
|
[3]
|
Laban, M., Metawee, H., Elyan, A., Kamal, M., Kamel, M. and Mansour, G. (2007) Three-dimensional ultrasound and three-dimensional power Doppler in the assessment of ovarian tumors. International Journal of Gynecology & Obstetrics, 99, 201-205.
http://dx.doi.org/10.1016/j.ijgo.2007.03.027
|
[4]
|
Mansour, G.M., El-Lamie, I.K., El-Sayed, H.M., Ibrahim, A.M., Laban, M., Abou-Louz, S.K., Abd Allah, M.Y., El-Mahallawi, M.N., El-Lamie, K.I. and Gad-Allah, M. (2009) Adnexal mass vascularity assessed by 3-dimensional power Doppler: Does it add to the risk of malignancy index in prediction of ovarian malignancy?: Four hundred-case study. International Journal of Gynecological Cancer, 19, 867-872.
http://dx.doi.org/10.1111/IGC.0b013e3181a8335e
|
[5]
|
Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J. and Cronin, K.A., Eds. (2013) SEER Cancer Statistics Review, National Cancer Institute, Bethesda. http://seer.cancer. gov/csr/1975_2010/
|
[6]
|
Manjunath, A.P., Pratapkumar, A.P. and Sujatha, K. (2001) Comparison of three risk-of-malignancy indices in evaluation of pelvic masses. Gynecologic Oncology, 81, 225-229. http://dx.doi.org/10. 1006/gyno.2001.6122
|
[7]
|
Yuen, P.M., Yu, K.M. and Yip, S.K. (1997) A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. American Journal of Obstetrics & Gynecology, 177, 109-114.
http://dx.doi.org/10.1016/S0002-9378(97)70447-2
|
[8]
|
Benedet, J.L., Hacker, N.F. and Ngan, H.Y.S. (2000) Staging classifications and clinical practice guidelines of gynaecologic cancers. International Journal of Gynecology & Obstetrics, 70, 207-312.
http://dx.doi.org/10.1016/S0020-7292(00)00300-3
|
[9]
|
Jacobs, I., Oram, D., Fairbanks, J., et al. (1990) A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British Journal of Obstetrics and Gynaecology, 97, 922-929.
http://dx.doi.org/10.1111/j.1471-0528.1990. tb02448.x
|
[10]
|
Davies, A.P., Jacobs, I., Woolas, R., Fish, A. and Oram, D. (1993) The adnexal mass: Benign or malignant? Evaluation of a risk of malignancy index. British Journal of Obstetrics and Gynaecology, 100, 927-931.
http://dx.doi.org/10.1111/j.1471-0528.1993.tb15109.x
|
[11]
|
Tingulstad, S., Hagen, B. and Skjeldestad, F.E. (1996) Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. British Journal of Obstetrics and Gynaecology, 103, 826-831.
http://dx.doi.org/10.1111/ j.1471-0528.1996.tb09882.x
|
[12]
|
Andersen, E.S., Knudsen, A., Rix, P., et al. (2003) Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecologic Oncology, 90, 109-112.
http://dx.doi.org/10.1016/S0090-8258(03)00192-6
|
[13]
|
Hu, L., Hofmann, J., Holash, J., Yancopoulos, G.D., Sood, A.K. and Jaffe, R.B. (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clinical Cancer Research, 11, 6966-6971. http://dx.doi.org/10.1158/1078-0432.CCR-05-0910
|
[14]
|
Kidron, D., Bernheim, J., Aviram, R., Cohen, I., Fishman, A., Beyth, Y. and Tepper, R. (1999) Resistance to blood flow in ovarian tumors: Correlation between resistance index and histological pattern of vascularization. Ultrasound in Obstetrics & Gynecology, 13, 425-430.
http://dx.doi.org/10.1046/j. 1469-0705.1999.13060425.x
|
[15]
|
Robati, M., Ghaderi, A., Mehraban, M., Shafizad, A., Nasrolahi, H. and Mohammad, M. (2013) Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Archives of Gynecology and Obstetrics, 288, 859-865.
http://dx.doi.org/10.1007/s00404-013-2819-7
|
[16]
|
Cooper, B.C., Ritchie, J.M., Broghammer, C.L., Coffin, J., Sorosky, J.I., Buller, R.E., Hendrix, M.J. and Sood, A.K. (2002) Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clinical Cancer Research, 8, 3193-3197.
|
[17]
|
Harlozinska, A., Sedlaczek, P., Kulpa, J., Grybos, M., Wójcik, E., Van Dalen, A. and Einarsson, R. (2004) Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Research, 24, 1149-1157.
|
[18]
|
Demirkiran, F., Kumbak, B., Bese, T., Arvas, M., Benian, A., Aydin, S., Uzun, H., Sanioglu, C., Aydinli, K. and K?sebay, D. (2003) Vascular endothelial growth factor in adnexal masses. International Journal of Gynecology & Obstetrics, 83, 53-58.
http://dx.doi.org/10.1016/S0020-7292(03)00208-X
|
[19]
|
Tanir, H.M., Ozalp, S., Yalcin, O.T., Colak, O., Akcay, A. and Senses, T. (2003) Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. European Journal of Gynaecological Oncology, 24, 271-274.
|
[20]
|
Lutgendorf, S.K., Johnsen, E.L., Cooper, B., Anderson, B., Sorosky, J.I., Buller, R.E. and Sood, A.K. (2002) Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 95, 808-815.
http://dx.doi.org/10.1002/cncr.10739
|
[21]
|
Obermair, A., Tempfer, C., Hefler, L., Preyer, O., Kaider, A., Zeillinger, R., Leodolter, S. and Kainz, C. (1998) Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. British Journal of Cancer, 77, 1870-1874.
http://dx.doi.org/10.1038/bjc.1998.311
|
[22]
|
Mu, J., Abe, Y., Tsutsui, T., Yamamoto, N., Tai, X.G., Niwa, O., Tsujimura, T., Sato, B., Terano, H., Fujiwara, H. and Hamaoka, T. (1996) Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Japanese Journal of Cancer Research, 87, 963-971.
http://dx.doi.org/10.1111/j.1349-7006.1996.tb02127.x
|